Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.65 (
Der p 1
)
346
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
House dust mites Dermatophagoides pteronyssinus (Dpt) are among the most frequent causes of allergy symptoms in Europe.
Der p 1
is one of the major allergenic compounds of Dpt and the pathological
Der p 1
-specific B cells play a key role as producers of allergen-binding antibodies. The selective elimination of these cells by artificial protein molecules which inhibit the production of Dpt-recognizing IgE antibodies is a perspective therapeutic goal of allergy. A protein engineered chimeric molecule has been constructed, which binds
Der p 1
-specific B cells via their BCR and suppresses selectively the production of anti-
Der p 1
antibodies via
CR1
. The synthetic peptide
Der p 1
p52-71 and an anti-CD35 monoclonal antibody were used for the construction of
Der p 1
chimera. The functional effects of engineered antibodies were analyzed in vitro using PBMCs from allergy patients. Significant inhibition of allergen-specific proliferation and reduction of
Der p 1
-IgE antibody production were observed after treatment of PBMCs from allergic patients with
Der p 1
-peptide chimera. Culturing of these PBMCs in the presence of the chimeric molecule increased the percentage of apoptotic (Annexin V-positive) B lymphocytes, but not T lymphocytes.
...
PMID:Suppression of allergen-specific B lymphocytes by chimeric protein-engineered antibodies. 2402 74